Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T J Herzog

Showing results (1-10 of 53) with videos related to

Pageof 6
Sort By:
Cytokine|May 1, 1992
Comparison of the cytostatic and cytolytic activity of tumor necrosis factor-alpha and interleukin 1 alpha in human malignant cell linesT J Herzog, J L Collin
Current Opinion in Oncology|September 7, 2000
Gestational trophoblastic diseases: new standards for therapyD E Cohn, T J Herzog
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 7, 2007
The emerging role of epidermal growth factor receptor inhibitors in ovarian cancerM J Palayekar, T J Herzog
Clinical Obstetrics and Gynecology|November 1, 2001
Current management of patients with invasive cervical carcinomaP W Grigsby, T J Herzog
The Journal of Reproductive Medicine|August 1, 1991
Adenocarcinoma in a single horn of a bicornuate uterus. A case reportT J Herzog, R Fry, N Husseinzadeh
Obstetrics and Gynecology|November 13, 2001
Meigs' syndrome with an elevated CA 125 from benign Brenner tumorsB M Buttin, D E Cohn, T J Herzog
Academic Radiology|May 1, 1997
Technique for performing direct lymphangiography in pigsD M Hovsepian, J S Wu, T J Herzog
Gynecologic Oncology|March 4, 1999
Interferon-gamma and tumor necrosis factor-alpha induce synergistic cytolytic effects in ovarian cancer cell lines-roles of the TR60 and TR80 tumor necrosis factor receptorsE R Kost, D G Mutch, T J Herzog
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 17, 2007
Clinical applications of immunohistochemistry in gynecological malignanciesJ Shutter, K A Atkins, K Ghartey, et al.
Genomics|April 7, 1999
A 1-Mb bacterial clone contig spanning the endometrial cancer deletion region at 1p32-p33M F Arlt, M Li, T J Herzog, et al.
Pageof 6

Showing results (1-10 of 53) with videos related to

Sort By:
Pageof 6
Cytokine|May 1, 1992
Comparison of the cytostatic and cytolytic activity of tumor necrosis factor-alpha and interleukin 1 alpha in human malignant cell linesT J Herzog, J L Collin
Current Opinion in Oncology|September 7, 2000
Gestational trophoblastic diseases: new standards for therapyD E Cohn, T J Herzog
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 7, 2007
The emerging role of epidermal growth factor receptor inhibitors in ovarian cancerM J Palayekar, T J Herzog
Clinical Obstetrics and Gynecology|November 1, 2001
Current management of patients with invasive cervical carcinomaP W Grigsby, T J Herzog
The Journal of Reproductive Medicine|August 1, 1991
Adenocarcinoma in a single horn of a bicornuate uterus. A case reportT J Herzog, R Fry, N Husseinzadeh
Obstetrics and Gynecology|November 13, 2001
Meigs' syndrome with an elevated CA 125 from benign Brenner tumorsB M Buttin, D E Cohn, T J Herzog
Academic Radiology|May 1, 1997
Technique for performing direct lymphangiography in pigsD M Hovsepian, J S Wu, T J Herzog
Gynecologic Oncology|March 4, 1999
Interferon-gamma and tumor necrosis factor-alpha induce synergistic cytolytic effects in ovarian cancer cell lines-roles of the TR60 and TR80 tumor necrosis factor receptorsE R Kost, D G Mutch, T J Herzog
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 17, 2007
Clinical applications of immunohistochemistry in gynecological malignanciesJ Shutter, K A Atkins, K Ghartey, et al.
Genomics|April 7, 1999
A 1-Mb bacterial clone contig spanning the endometrial cancer deletion region at 1p32-p33M F Arlt, M Li, T J Herzog, et al.
Pageof 6